Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ipratropium bromide monohydrate, quantity: 522 microgram (equivalent: ipratropium bromide, qty 500 microgram) - inhalation, conventional - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for moderate asthma attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery; use during assisted ventilation with a respirator.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ipratropium bromide monohydrate, quantity: 261 microgram (equivalent: ipratropium bromide, qty 250 microgram) - inhalation, conventional - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - for moderate asthma attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery; use during assisted ventilation with a respirator.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adenosine, quantity: 6 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: adenosine viatris is indicated for the rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications: adenosine viatris is indicated as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine viatris is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be used only when, despite all diagnostic attempts, doubt still persists. adenosine viatris can also be used for improved diagnostic sensitivity of intracavity electrophysiological investigations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lenalidomide, quantity: 5 mg - capsule - excipient ingredients: colloidal anhydrous silica; pregelatinised starch; sodium stearylfumarate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; gelatin; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide viatris is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide viatris is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide viatris is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lenalidomide, quantity: 25 mg - capsule - excipient ingredients: sodium stearylfumarate; pregelatinised starch; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin - multiple myeloma (mm),lenalidomide viatris is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide viatris is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide viatris is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: pregelatinised starch; croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid; titanium dioxide; gelatin - multiple myeloma (mm),lenalidomide viatris is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide viatris is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide viatris is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lenalidomide, quantity: 10 mg - capsule - excipient ingredients: croscarmellose sodium; sodium stearylfumarate; colloidal anhydrous silica; pregelatinised starch; microcrystalline cellulose; titanium dioxide; indigo carmine; iron oxide yellow; gelatin; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - multiple myeloma (mm),lenalidomide viatris is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide viatris is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide viatris is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - tobramycin, quantity: 28 mg - capsule, hard - excipient ingredients: hypromellose; titanium dioxide; calcium chloride dihydrate; carnauba wax; carrageenan; potassium chloride; butan-1-ol; distearoylphosphatidylcholine; isopropyl alcohol; indigo carmine aluminium lake; sulfuric acid; shellac; purified water; propylene glycol - tobi solution and tobi podhaler are indicated for the management of cystic fibrosis patients with p. aeruginosa infections. safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with fev1 less than or equal to 25 % or greater than or equal to 80 % predicted at screening, or patients colonized with burkholderia cepacia. (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - tobramycin, quantity: 60 mg/ml - inhalation, conventional - excipient ingredients: water for injections; sodium hydroxide; sulfuric acid; sodium chloride - tobi is indicated for the management of cystic fibrosis patients with p.aeruginosa infections. safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with fev,<25% or >75% predicted, or patients colonised with burkolderia cepacia (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moclobemide, quantity: 300 mg - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; macrogol 6000; titanium dioxide; lactose monohydrate; sodium starch glycollate; hypromellose; povidone; purified talc; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - treatment of major depression.